| 31.57 1.15 (3.78%) | 04-27 11:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.53 | 1-year : | 43.84 |
| Resists | First : | 32.13 | Second : | 37.53 |
| Pivot price | 28.8  |
|||
| Supports | First : | 25.08 | Second : | 20.71 |
| MAs | MA(5) : | 30.89  |
MA(20) : | 27.51 |
| MA(100) : | 23.62 |
MA(250) : | 21.63 |
|
| MACD | MACD : | 2 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 84.4 |
D(3) : | 85.2 |
| RSI | RSI(14): 70.4 |
|||
| 52-week | High : | 32.13 | Low : | 16.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVBP ] has closed below upper band by 23.5%. Bollinger Bands are 74.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 31.28 - 31.43 | 31.43 - 31.58 |
| Low: | 29.56 - 29.75 | 29.75 - 29.93 |
| Close: | 30.07 - 30.37 | 30.37 - 30.67 |
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Mon, 06 Apr 2026
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet - Yahoo Finance
Tue, 10 Mar 2026
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tue, 10 Mar 2026
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Yahoo Finance
Tue, 08 Jul 2025
Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering - Mintz
Fri, 25 Apr 2025
AVBP Stock Price, News & Analysis - Stock Titan
Sun, 16 Jun 2024
Mintz Advises on ArriVent BioPharma’s Upsized IPO on the Nasdaq Global Market - Mintz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 96.6 (%) |
| Shares Short | 7,760 (K) |
| Shares Short P.Month | 7,000 (K) |
| EPS | -4.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.5 % |
| Return on Equity (ttm) | -58.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -161 (M) |
| Levered Free Cash Flow | -102 (M) |
| PE Ratio | -7.22 |
| PEG Ratio | 0 |
| Price to Book value | 4.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|